

December 24, 2015  
SymBio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President & Chief Executive Officer

**SymBio Files Supplemental NDA for TREAKISYM®  
in Chronic Lymphocytic Leukemia (Additional Indication)**

TOKYO, Japan, December 24, 2015 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, “SymBio,”) announced today its submission of a supplemental New Drug Application (“sNDA”) to the Pharmaceuticals and Medical Devices Agency (“PMDA”) in Japan for TREAKISYM® (“bendamustine”) in the treatment of Chronic Lymphocytic Leukemia (CLL). SymBio received marketing approval for TREAKISYM® on October 27, 2010, to treat Japanese patients with relapsed or refractory Lg-NHL and MCL.

Submission of this sNDA will not impact the Company’s financial forecast for FY2015.

**[Contact]**

**Investor Relations**

Tel: +81 (0)3 5472 1125

**[Glossary]**

**About Bendamustine Hydrochloride (TREAKISYM®)**

In partnership with Eisai Co., Ltd., SymBio received marketing approval for TREAKISYM® (SyB L-0501) in October, 2010, to treat Japanese patients with relapsed/refractory (r/r) low-grade non-Hodgkin’s lymphoma (Lg-NHL) and mantle cell lymphoma (MCL).

**About Chronic Lymphocytic Leukemia (CLL)**

CLL is a cancer of the blood characterized by the progressive accumulation of functionally incompetent lymphocytes, a type of white blood cell produced by the bone marrow and organs of the lymphatic system. The number of CLL patients in Japan is estimated to be around 2,000. In the US and EU, bendamustine has been approved for the treatment of CLL where the disease accounts for an estimated 30% of all leukemia cases. Due to the lack of effective therapies in Japan, CLL patients are seriously underserved and a high unmet medical need exists for the development of an effective alternative therapy.

**About SymBio Pharmaceuticals Limited**

SymBio Pharmaceuticals Limited was established in March, 2005, by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. The company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading specialty pharmaceutical company in Asia Pacific dedicated to addressing underserved medical needs with main therapeutic focus on oncology, hematology and pain management.